Scientists at The University of Texas Health Science Center at Houston (UTHealth) and Baylor College of Medicine may soon succeed in diagnosing and treating pancreatic cancer, one of the most lethal and hard-to-treat types of cancer.
The investigators report in the an article published in the July 16 online edition EMBO Molecular Medicinethat they have identified a new molecular mechanism that contributes to the spread of malignant tumors in the pancreas. The hope is that drugs could one day be developed to block this pathway.[1]
Findings in this study define a novel signaling axis promoting pancreatic cancer growth, providing potential mechanistic insights on how a zinc transporter functions in cancer cells…
Cancer Incidence
Most people with pancreatic cancer die within one to two years of diagnosis and, according to the American Cancer Institute, it is expected that the diseases will claim 38,460 lives in the United States in 2013. There are currently no effective tests for early detection and no effective therapies for the fast-spreading form.
Zinc and Pancreatic Cancer
The study focused on the previously established link between zinc and pancreatic cancer and sought to identify a molecular mechanism responsible for the elevated levels found in human and animal cells. Zinc is an essential trace element and small amounts are important for human health.
Commenting on the link between zinc and pancreatic cancer, Min Li, Ph.D., the study?s senior author and associate professor and director of the Cancer Research Program in the Vivian L. Smith Department of Neurosurgeryat the UTHealth Medical School, said: ?We were the first to show that zinc transporter ZIP4 was a marker for pancreatic cancer. We knew there was a link but we didn?t know what it was.? Li is a member of the faculty of The University of Texas Graduate School of Biomedical Sciencesat Houston, which is a joint venture of UTHealth and The University of Texas MD Anderson Cancer Center.
Master switch
“Zinc levels are regulated by ZIP4, which acts as a master switch, and the researchers designed experiments to determine what happens when the switch is flipped on, Li,” explained.In an animal model of pancreatic cancer, the scientists observed how the initiation of ZIP4 triggered the activation of two downstream genes, which in turn accounts for the increased tumor growth. Scientists describe this as a signaling cascade.
Novel Biological Role
?Pancreatic cancer is among the worst of all cancers. It is imperative to define the mechanism of this deadly disease. We have recently demonstrated a novel biological role for the zinc transporter ZIP4 in pancreatic cancer; however, the molecular pathway controlling this phenomenon remains elusive. This study provides a comprehensive mechanism for ZIP4-mediated pancreatic cancer growth involving the activation of a transcription factor CREB and an oncogenic miR-373, and reduction in key tumor suppressor genes,? noted Yuqing Zhang, Ph.D., co-first author of the study.
Jingxuan Yang, Ph.D., co-first author and research scientist at the UTHealth Medical School, explained, ?Our findings in this study define a novel signaling axis promoting pancreatic cancer growth, providing potential mechanistic insights on how a zinc transporter functions in cancer cells and may have broader implications as abnormal zinc concentration in the cells plays an important role in many other diseases.?
Future therapeutic strategies
?The results we reported in this study may help the design of future therapeutic strategies targeting the zinc transporter and microRNA pathways to treat pancreatic cancer,? said Xiaobo Cui, M.D., Ph.D., study co-first author and postdoctoral research fellow at the UTHealth Medical School.
For more information:
[1] Zhang Y, Yang J, Cui X, Chen Y, Zhu VF, Hagan JP, Wang H, Yu X, et al. A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth.EMBO Mol Med. 2013 Jul 16. doi: 10.1002/emmm.201302507. [Epub ahead of print][Article][PubMed]
Copyright ? 2013 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.
